MIRA
INFORM REPORT
|
Report Date : |
28.05.2007 |
IDENTIFICATION DETAILS
|
Name : |
CATALYST CLINICAL SERVICES PRIVATE LIMITED |
|
|
|
|
Registered Office : |
119 State Bank Colony, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.03.2006 |
|
|
|
|
Date of Incorporation : |
21.04.2004 |
|
|
|
|
Com. Reg. No.: |
55 – 125941 |
|
|
|
|
CIN No.: [Company
Identification No.] |
U24239DL2004PTC125941 |
|
|
|
|
TAN No.: [Tax
Deduction & Collection Account No.] |
DELC07780D |
|
|
|
|
PAN No.: [Permanent
Account No.] |
AACCC3887G |
|
|
|
|
Legal Form : |
Private Limited Liability Company |
|
|
|
|
Line of Business : |
Exporting, Importing, Packaging and Dealing in and disposing of all kinds
of pharmaceutical products substances such as medicines, drugs, cosmetics,
therapeutic substances, veterinary medicines, pharmaceutical raw material
drug intermediates & chemical product. Contract Research in Health Care and Biotechnology. |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems comparatively
below average/normal. |
Small |
|
Maximum Credit Limit : |
USD 900 |
|
|
|
|
Status : |
Small Company |
|
|
|
|
Payment Behaviour : |
Usually correct |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a relatively small company having satisfactory track
records. Directors are reported as
experienced and respectable businessmen.
Trade relations are reported as fair.
Business is active. Payments
are however reported as usually correct and as per commitments. The company can be considered for small business dealings at usual
trade terms and conditions. |
LOCATIONS
|
Registered Office : |
119 State Bank Colony, |
|
Tel. No.: |
91-11-42384005 |
|
Telefax No.: |
91-11-27466248 |
|
E-Mail : |
|
|
Website : |
DIRECTORS
|
Name : |
Smt. Aruna Gupta |
|
Designation : |
Director |
|
Address : |
D – 21, |
|
Date of Birth/Age : |
23.07.1976 |
|
Date of Appointment : |
21.04.2004 |
|
Date of Ceasing : |
15.03.2005 |
|
|
|
|
Name : |
Mr. Pankaj Gupta |
|
Designation : |
Director |
|
Address : |
119, State Bank of Colony, |
|
Date of Birth/Age : |
26.06.1972 |
|
Date of Appointment : |
21.04.2004 |
|
|
|
|
Name : |
Mr. Sunil Garg |
|
Designation : |
Director |
|
Address : |
D – 17, Sector – 40, Noida – 201301 |
|
Date of Birth/Age : |
14.03.1979 |
|
Date of Appointment : |
21.09.2005 |
|
|
|
|
Name : |
Mr. Sanjay Gupta |
|
Designation : |
Director |
|
Address : |
D – 21, |
|
Date of Birth/Age : |
18.04.1973 |
|
Date of Appointment : |
30.09.2005 |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
|
Names of Shareholders |
|
No. of Shares |
|
Smt. Aruna Gupta |
|
6000 |
|
Mr. Pankaj Gupta |
|
2000 |
|
Mr. Sunil Garg |
|
2000 |
As on 31.03.2006
|
Names of Shareholders |
|
Percentage of
Holding |
|
Directors or relatives of directors |
|
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Exporting, Importing, Packaging and Dealing in and disposing of all
kinds of pharmaceutical products substances such as medicines, drugs,
cosmetics, therapeutic substances, veterinary medicines, pharmaceutical raw
material drug intermediates & chemical product. Contract Research in Health Care and Biotechnology. |
GENERAL INFORMATION
|
Bankers : |
State Bank of |
|
|
|
|
Banking Relations
: |
-- |
|
|
|
|
Auditors : |
|
|
Name : |
Manoj Kumar Gupta & Company Chartered Accountants |
|
Address : |
B – 4/1, |
|
PAN No.: |
AGMPG8762B |
CAPITAL STRUCTURE
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
10000 |
Equity Shares |
Rs. 10/- each |
Rs. 0.100 million |
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
10000 |
Equity Shares |
Rs. 10/- each |
Rs. 0.100 million |
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
|
31.03.2006 |
31.03.2005 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
|
0.100 |
0.100 |
|
|
2] Share Application Money |
|
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
|
0.130 |
0.077 |
|
|
4] (Accumulated Losses) |
|
0.000 |
0.000 |
|
|
NETWORTH |
|
0.230 |
0.177 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
|
0.000 |
0.000 |
|
|
2] Unsecured Loans |
|
0.000 |
0.000 |
|
|
TOTAL BORROWING |
|
0.000 |
0.000 |
|
|
DEFERRED TAX LIABILITIES |
|
0.021 |
0.002 |
|
|
|
|
|
|
|
|
TOTAL |
|
0.251 |
0.179 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
|
0.122 |
0.094 |
|
|
Capital work-in-progress |
|
0.000 |
0.000 |
|
|
|
|
|
|
|
|
INVESTMENT |
|
0.000 |
0.000 |
|
|
DEFERREX TAX ASSETS |
|
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
|
0.000 |
0.000 |
|
|
Sundry Debtors |
|
0.025 |
0.000 |
|
|
Cash & Bank Balances |
|
0.180 |
0.154 |
|
|
Other Current Assets |
|
0.000 |
0.000 |
|
|
Loans & Advances |
|
0.059 |
0.042 |
|
Total
Current Assets |
|
0.264 |
0.196 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Current Liabilities |
|
0.083 |
0.066 |
|
|
Provisions |
|
0.052 |
0.045 |
|
Total
Current Liabilities |
|
0.135 |
0.111 |
|
|
Net Current Assets |
|
0.129 |
0.085 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
|
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
|
0.251 |
0.179 |
|
PROFIT & LOSS
ACCOUNT
|
PARTICULARS |
|
31.03.2006 |
31.03.2005 |
|
Sales Turnover |
|
2.149 |
2.184 |
|
Other Income |
|
0.000 |
0.000 |
|
Total Income |
|
2.149 |
2.184 |
|
|
|
|
|
|
Profit/(Loss) Before Tax |
|
0.128 |
0.124 |
|
Provision for Taxation |
|
0.075 |
0.047 |
|
Profit/(Loss) After Tax |
|
0.053 |
0.077 |
|
|
|
|
|
|
Total Expenditure |
|
2.021 |
2.060 |
KEY RATIOS
|
PARTICULARS |
|
|
31.03.2006 |
31.03.2005 |
|
PAT / Total Income |
(%) |
|
2.46 |
3.52 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
|
5.95 |
5.67 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
|
33.16 |
42.75 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
|
0.55 |
0.70 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
|
0.58 |
0.62 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
|
1.95 |
1.77 |
LOCAL AGENCY FURTHER INFORMATION
WEBSITE DETAILS
Subject is a Contract Research Organization that acts as a strategic partner
to the organizations in healthcare and biotechnology, making them winner by
building on their core competence and empowering them to counter threats.
The primary focus area in healthcare is Clinical Trial Management &
Execution, Training & Development and Business Process Mapping (development
of Standard Operating Procedures). Catalyst could be a partner to the
organization either for a single service or for the full range of our
professional services customized to cater to individual needs.
The major achievement of the company is the pioneering and flagship publication
- "Clinical
Quest TM", which is
subject has ability to bring together all the key elements required for the
successful and effective management of clinical trials by linking people,
processes and technologies.
Quality is assured via ICH-GCP
compliant Standard Operating Procedures, internal audits and exceptional catalyst training to all its members.
Their core team includes an array of highly competent and experienced clinical
research professionals having a rich experience of conducting ICH-GCP trials.
The Advisory panel includes highly experienced clinical research professionals
from
Subject’s value to firmly maintain the professionalism, service, flexibility,
quality, dedication & work ethics.
Strengths
Service Excellence
Total Quality Management
GCP adherence and compliance
Unparalleled value for money
Young and motivated team
Thorough understanding of local & global regulatory
policies & processes
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper payments
to government officials for engaging in prohibited transactions or with
designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.40.60 |
|
|
1 |
Rs.80.65 |
|
Euro |
1 |
Rs.54.55 |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
2 |
|
PAID-UP CAPITAL |
1~10 |
3 |
|
OPERATING SCALE |
1~10 |
3 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
4 |
|
--PROFITABILIRY |
1~10 |
2 |
|
--LIQUIDITY |
1~10 |
3 |
|
--LEVERAGE |
1~10 |
3 |
|
--RESERVES |
1~10 |
3 |
|
--CREDIT LINES |
1~10 |
3 |
|
--MARGINS |
-5~5 |
- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
NO |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
YES |
|
--AFFILIATION |
YES/NO |
NO |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
26 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit consideration.
Capability to overcome financial difficulties seems comparatively below
average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|